Langerhans cell histiocytosis: current advances in molecular pathogenesis
Langerhans cell histiocytosis (LCH) is a rare and clinically heterogeneous hematological
disease characterized by the accumulation of mononuclear phagocytes in various tissues …
disease characterized by the accumulation of mononuclear phagocytes in various tissues …
BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology
Langerhans cell histiocytosis (LCH) is a potentially fatal condition characterized by
granulomatous lesions with characteristic clonal mononuclear phagocytes (MNPs) …
granulomatous lesions with characteristic clonal mononuclear phagocytes (MNPs) …
Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders
E Cournoyer, J Ferrell, S Sharp, A Ray… - …, 2023 - pmc.ncbi.nlm.nih.gov
The standard treatment for Langerhans cell histiocytosis (LCH) is chemotherapy, although
the failure rates are high. Since MAP-kinase activating mutations are found in most cases …
the failure rates are high. Since MAP-kinase activating mutations are found in most cases …
Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis
F Jouenne, A Benattia, A Tazi - Current Opinion in Oncology, 2021 - journals.lww.com
Mitogen-activating protein kinase pathway alterations in Lan... : Current Opinion in Oncology
Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis : Current …
Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis : Current …
Notch-dependent cooperativity between myeloid lineages promotes Langerhans cell histiocytosis pathology
Langerhans cell histiocytosis (LCH) is a potentially fatal neoplasm characterized by the
aberrant differentiation of mononuclear phagocytes, driven by mitogen-activated protein …
aberrant differentiation of mononuclear phagocytes, driven by mitogen-activated protein …
Lineage switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis
Most children with high-risk Langerhans cell histiocytosis (LCH) have BRAF V600E
mutation. BRAF V600E alleles are detectable in myeloid mononuclear cells at diagnosis but …
mutation. BRAF V600E alleles are detectable in myeloid mononuclear cells at diagnosis but …
Bone marrow–derived myeloid progenitors as driver mutation carriers in high-and low-risk Langerhans cell histiocytosis
Y Xiao, AGS van Halteren, X Lei, J Borst… - Blood, The Journal …, 2020 - ashpublications.org
Langerhans cell histiocytosis (LCH) is a myeloid neoplasia, driven by sporadic activating
mutations in the MAPK pathway. The misguided myeloid dendritic cell (DC) model proposes …
mutations in the MAPK pathway. The misguided myeloid dendritic cell (DC) model proposes …
Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAFV600E
P Milne, H Abhyankar, B Scull, P Singh… - Blood …, 2022 - ashpublications.org
Author contributions and disclosures: Paul Milne designed research, performed
experiments, analyzed data and wrote the paper Harshal Abhyankar performed experiments …
experiments, analyzed data and wrote the paper Harshal Abhyankar performed experiments …
Identification of immune-related hub genes and potential molecular mechanisms involved in COVID-19 via integrated bioinformatics analysis
R Zhu, Y Zhao, H Yin, L Shu, Y Ma, Y Tao - Scientific Reports, 2024 - nature.com
COVID-19, caused by the SARS-CoV-2 virus, poses significant health challenges
worldwide, particularly due to severe immune-related complications. Understanding the …
worldwide, particularly due to severe immune-related complications. Understanding the …
Pulmonary Langerhans cell histiocytosis–an update on pathogenesis and treatment
F Jouenne, A Benattia, A Tazi - Current Opinion in Pulmonary …, 2023 - journals.lww.com
Pulmonary Langerhans cell histiocytosis – an update on patho... : Current Opinion in Pulmonary
Medicine Pulmonary Langerhans cell histiocytosis – an update on pathogenesis and treatment …
Medicine Pulmonary Langerhans cell histiocytosis – an update on pathogenesis and treatment …